康宁杰瑞制药-B:JSKN003获美国FDA批准开展一项治疗不限HER2表达水平的PROC的II期临床研究

格隆汇
Jul 31

格隆汇7月31日丨康宁杰瑞制药-B(09966.HK)宣布,JSKN003已获美国食品药品监督管理局("FDA")批准,在美国开展一项I I期临床研究(研究编号:JSKN003-202)。JSKN003-202是JSKN003的一项随机、开放式标签、多中心的II期临床研究,用于治疗铂耐药复发性上皮性巢癌、原发性腹膜癌或输管癌(统称为铂耐药巢癌,"PROC"),且不限人表皮生长因子受体2("HER2...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10